Safety of intravenous immunoglobulin treatment.
In a prospective clinical and biochemical study of 16 patients treated with high doses of an immunoglobulin product that had been modified for intravenous use by mild pepsin treatment at pH 4 no evidence of hepatitis could be found. This contrasts with recent reports that intravenous immunoglobulin products can apparently transmit non-A, non-B hepatitis.
D000410:Alanine Transaminase / Q000097:blood; D003257:Consumer Product Safety; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006526:Hepatitis C / Q000635:transmission; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000592:standards; D007275:Injections, Intravenous; D011446:Prospective Studies; D011696:Purpura, Thrombocytopenic / Q000097:blood / Q000628:therapy
D006514:Hepatitis B Surface Antigens; D007136:Immunoglobulins; D000410:Alanine Transaminase